Merit Medical Systems Inc. (MMSI)
NASDAQ: MMSI · Surgical & Medical Instruments & Apparatus · South Jordan, UT
Our rating: Neutral
Neutral reaffirmed at $86.24, moderate conviction, October 30, 2026.
Breaks if: The neutral call turns Positive if trailing-twelve-month revenue growth lifts above 14% and net margin expands to 11% or higher across two consecutive quarterly reports — evidence that operating leverage is arriving ahead of expectations. It turns Cautious if trailing revenue growth decelerates below 7% or annualized free cash flow falls below $160 million, either condition observed within the next four quarterly reports.
Key figures
| Market value | $5.1B |
|---|---|
| Revenue, last 12 months | $1.6B |
| Net income, last 12 months | $160M |
| Free cash flow, last 12 months | $204M |
| Price to earnings | 31.6× |
| Free cash flow yield | 4.0% |
| Dividend yield | 0.0% |
| Operating margin | 13.5% |
| Return on equity | 9.8% |
| Beta to the S&P 500 | 0.69 |
| Volatility, annualized | 28.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $416M | 8.4% | $0.70 | $53M |
| June 30, 2026 | $419M | 9.5% | $0.65 | $52M |
| March 31, 2026 | $382M | 7.5% | $0.68 | $25M |
| December 31, 2025 | $394M | 10.9% | $0.64 | $74M |
| September 30, 2025 | $384M | 13.0% | $0.46 | $53M |
| June 30, 2025 | $382M | 13.2% | $0.54 | $70M |
| March 31, 2025 | $355M | 9.8% | $0.49 | $20M |
| December 31, 2024 | $355M | 9.4% | $0.46 | $65M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.43B: Claude 72%, Gemini 80%, Mistral 45%
- Diluted earnings per share are at least $0.64: Claude 60%, Gemini 95%, Mistral 75%
- Free cash flow for the quarter is at least $0.07B: Claude 45%, Gemini 85%, Mistral 35%
9 ledger entries and 61 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.